Author(s): Shiqiu Xiong
Hepatocellular Carcinoma (HCC) is the most common primary liver cancer with high mortality. Because of the limitation on the conventional therapeutic options and immunological characters of this disease, variable immunotherapy strategies for HCC have been designed and investigated. A few of them look promising. In this review, we comprehensively summarized recent and novel immunotherapies for HCC, with a particular focus on clinical trials on the basis of their physiological rationales for these strategies. Insights into these clinical progress and their ideologies are essential to improve efficacy and clinical outcome of these immunotherapies.
